1. 1) C. Diabetes, G. Complications Trial Research, D.M. Nathan, S. Genuth, J. Lachin, P. Cleary, O. Crofford, M. Davis, L. Rand, and C. Siebert: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 329, 977–986 (1993).
2. 2) Y. Tahara and K. Shima: Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care, 18, 440–447 (1995).
3. 3) M. Koga and S. Kasayama: Clinical impact of glycated albumin as another glycemic control marker. Endocr. J., 57, 751–762 (2010).
4. 4) T. Suwa, A. Ohta, T. Matsui, R. Koganei, H. Kato, T. Kawata, Y. Sada, S. Ishii, A. Kondo, K. Murakami, T. Katabami, and Y. Tanaka: Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr. J., 57, 135–140 (2010).
5. 5) A. Sato: Indicators of glycemic control --hemoglobin A1c (HbA1c), glycated albumin (GA), and 1,5-anhydroglucitol (1,5-AG). Rinsho Byori, 62, 45–52 (2014).